Monocaprin eye drop formulation to combat antibiotic resistant gonococcal blindness.

Area of Science:

• Ophthalmology
• Microbiology
• Drug Delivery

Background:

• Neisseria gonorrhoeae is a major cause of bacterial eye infections, leading to blindness.
• Antibiotic resistance in N. gonorrhoeae poses a significant public health threat.
• Infants are particularly vulnerable to gonococcal ophthalmia neonatorum.

Purpose of the Study:

• To evaluate monocaprin as a potential therapeutic agent for bacterial eye infections.
• To develop and assess a stable, non-irritating eye drop formulation containing monocaprin.
• To investigate the antimicrobial efficacy and safety of monocaprin formulations against N. gonorrhoeae.

Main Methods:

• Assessed monocaprin formulations using analytical techniques.
• Evaluated antimicrobial activity in vitro and in ex vivo ocular infection models.
• Tested formulations for ocular irritation potential and long-term stability.

Main Results:

• Monocaprin demonstrated rapid killing of Neisseria gonorrhoeae and other bacteria.
• Monocaprin-containing eye drop formulations were non-irritating in ocular assays.
• Formulations retained antimicrobial activity after three years and were superior to povidone-iodine preparations.

Conclusions:

• Monocaprin is a promising antimicrobial agent for treating bacterial eye infections.
• A 0.25% monocaprin in 1% HPMC with 1% polysorbate 20 formulation is recommended for further development.
• Monocaprin offers a safe and effective alternative for combating antibiotic-resistant N. gonorrhoeae in ocular infections.